The Issue is the Tissue

Researchers at the University of Colorado Health Sciences Center have found that an adenosine A2b receptor agonist from Bayer AG can alleviate pulmonary inflammation, edema and impaired gas exchange associated with acute lung injury.¹ The finding could be welcome news, as there are no FDA-approved drugs for the indication.

Tissue selectivity and treatment duration are likely to be key issues for the compound, as adenosine A2b receptor agonism has previously resulted in opposite effects-namely increased inflammation-in conditions including asthma and colitis...